Article
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
Journal of hepatology - 1 Apr 2006
Bain Vincent G, Kaita Kelly D, Yoshida Eric M, Swain Mark G, Heathcote E Jenny, Neumann Avidan U, Fiscella Michele, Yu Ren, Osborn Blaire L, Cronin Patrick W, Freimuth William W, McHutchison John G, Subramanian G Mani
Abstract excerpt
BACKGROUND/AIMS: Recombinant human albumin-interferon alfa (alb-IFN) is a novel 85.7-kD recombinant protein consisting of interferon alfa-2b genetically fused to human serum albumin. METHODS: A phase 2, open-label, dose-ranging study was conducted in IFN-alfa-naïve patients with genotype 1 chronic hepatitis C to evaluate the antiviral activity, safety, and pharmacokinetics of alb-IFN. Fifty-six patients were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.